Baillie Gifford & Co. lifted its position in Hutchison China MediTech Limited (NASDAQ:HCM) by 10.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 185,604 shares of the company’s stock after purchasing an additional 18,057 shares during the quarter. Baillie Gifford & Co. owned approximately 0.15% of Hutchison China MediTech Limited worth $5,062,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in shares of Hutchison China MediTech Limited by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock valued at $2,420,000 after purchasing an additional 7,400 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Hutchison China MediTech Limited in the 1st quarter valued at about $618,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Hutchison China MediTech Limited in the 2nd quarter valued at about $5,102,000. 4.08% of the stock is owned by hedge funds and other institutional investors.
Shares of Hutchison China MediTech Limited (HCM) opened at $29.57 on Friday. The company has a quick ratio of 1.73, a current ratio of 1.84 and a debt-to-equity ratio of 0.09.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/04/baillie-gifford-co-has-5-06-million-stake-in-hutchison-china-meditech-limited-hcm.html.
HCM has been the subject of a number of research analyst reports. BidaskClub raised Hutchison China MediTech Limited from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 13th. Canaccord Genuity upped their target price on Hutchison China MediTech Limited to $38.00 and gave the company a “buy” rating in a research report on Monday, October 16th.
Hutchison China MediTech Limited Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hutchison China MediTech Limited (NASDAQ:HCM).
What are top analysts saying about Hutchison China MediTech Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hutchison China MediTech Limited and related companies.